3. >>Deals

Torrent Picks Up Boehringer Diabetes Brands Ahead Of India Patent Expiry

GLP-1 Generics Coming In 2026

 
• By Vibha Ravi

Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.

A Business Deal
Torrent And Boehringer Ingelheim Work Out Deal For Anti-Diabetes Brands In India (Shutterstock)

Boehringer Ingelheim is cashing in on its diabetes franchise related to sodium glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin in India ahead of the local patent expiry for the molecule in March 2025.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Strategy